Could PCSK9 inhibitors be cost effective for all comers?

WASHINGTON - Treating all of the estimated 23 million individuals in the United States who would qualify for PCSK9 inhibitor therapy on the basis of current Food and Drug Administration indications...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news